BOULDER, Colo., July 28, 2016 /PRNewswire/ -- Array
BioPharma (NASDAQ: ARRY) ("Array"), a biopharmaceutical company
focused on the discovery, development and commercialization of
targeted small molecule drugs to treat patients afflicted with
cancer, announced it has appointed Jason
Haddock as Chief Financial Officer (CFO). Mr. Haddock's
appointment was effective today and he will be replacing
David Horin, who had been acting as
Array's interim CFO. We wish to thank Mr. Horin for his service and
commitment to Array. He will continue to provide services to
Array on a consulting basis.
Mr. Haddock has more than 15 years of financial and operational
experience in the biopharmaceutical industry. He held
leadership positions of increasing responsibility at Bristol-Myers
Squibb, a global pharmaceutical company with a strong focus on
immuno-oncology therapies, in a variety of accounting, planning,
commercial, analytical and business development capacities over
more than 13 years through 2015. Mr. Haddock most recently served
as CFO and Chief Operating Officer (COO) of BERG Health, an
oncology focused research, diagnostics and development company,
where he oversaw the implementation of financial and operational
processes, procedures and policies to transform and scale the
company's practices as it planned for growth and corporate
evolution.
"We are pleased to welcome Jason to Array's executive team
during a pivotal time for our company," said Ron Squarer, Array's
Chief Executive Officer. "He brings strong financial and
operational expertise across many therapeutic areas and in
commercial, medical and operational functions, and is well-versed
on the nuances and challenges in the pharmaceutical landscape. We
look forward to having Jason in this role as we continue to plan
for commercialization of two wholly-owned drugs in the US."
Array is approaching several significant near-term milestones,
including top-line results from the COLUMBUS Phase 3 pivotal trial
and a projected regulatory filing of binimetinib (MEK inhibitor) in
combination with encorafenib (BRAF inhibitor) in BRAF-mutant
melanoma.
"I am excited about the opportunity to join Array and look
forward to leveraging my industry experience to help strengthen the
Company's financial and operational performance," said Mr. Haddock.
"Array is well-positioned to capitalize on its robust drug pipeline
and I am confident we can successfully execute on its plan to drive
value for shareholders."
About Jason Haddock
Mr. Haddock held leadership positions of increasing responsibility
at Bristol-Myers Squibb over a period of more than 13 years. During
that time, he served in a variety of accounting, planning,
commercial, analytical and business development capacities for
high-growth business units, including Head of Finance for the
Worldwide Commercialization and Medical division, where he
orchestrated all strategic plan financial components for a
$16 billion portfolio. He also served
as an Executive Director of the U.S. Pharmaceutical Commercial
Operations unit, where he focused on designing a completely new
business model and operations to capitalize on future product
portfolio changes and market developments. Most recently, Mr.
Haddock served as CFO and COO at BERG Health, where he oversaw the
implementation of financial and operational processes, procedures
and policies to transform and scale the company's practices as it
planned for growth and corporate evolution.
Mr. Haddock earned his undergraduate degree in accounting from
Illinois State University and is a
Certified Management Accountant. He holds an MBA from Washington University in St. Louis where he completed the Executive
Program.
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Six registration studies are
currently advancing related to three cancer drugs. These programs
include binimetinib (MEK162), encorafenib (LGX818) and selumetinib
(AstraZeneca). For more information on Array, please go to
www.arraybiopharma.com.
Forward-Looking Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
about expectations concerning development milestones relating to
binimetinib and encorafenib and that events will occur that will
result in commercialized drugs or in greater value for Array. These
statements involve significant risks and uncertainties, including
those discussed in our most recent annual report filed on Form
10-K, in our quarterly reports filed on Form 10-Q, and in other
reports filed by Array with the Securities and Exchange Commission.
Because these statements reflect our current expectations
concerning future events, our actual results could differ
materially from those anticipated in these forward-looking
statements as a result of many factors. These factors include, but
are not limited to, our ability to continue to fund and
successfully progress internal research and development efforts and
to create effective, commercially viable drugs; our ability to
effectively and timely conduct clinical trials in light of
increasing costs and difficulties in locating appropriate trial
sites and in enrolling patients who meet the criteria for certain
clinical trials; risks associated with our dependence on
third-party service providers to successfully conduct clinical
trials within and outside the United
States; our ability to achieve and maintain profitability
and maintain sufficient cash resources; and our ability to attract
and retain experienced scientists and management. We are providing
this information as of July 28, 2016.
We undertake no duty to update any forward-looking statements to
reflect the occurrence of events or circumstances after the date of
such statements or of anticipated or unanticipated events that
alter any assumptions underlying such statements.
Photo - http://photos.prnewswire.com/prnh/20160727/393638
Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
CONTACT:
Tricia
Haugeto
(303) 386-1193
thaugeto@arraybiopharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-announces-appointment-of-jason-haddock-as-chief-financial-officer-300305285.html
SOURCE Array BioPharma Inc.